Skip to content

LA BRABANÇONNE PHARMA

Active
Private limited companyfounded 2025active for 1 yearBrabançonnelaan 139, 1030 Schaarbeek, BelgiumKBO/BCE: BE 1025.693.638
Summary

The computed 12-month bankruptcy probability of LA BRABANÇONNE PHARMA is 1.7% (moderate). The 2025 annual accounts show equity of €60,175 and a net result of -€39,825. Its solvency ranks better than 17% of 12,686 sector peers (NACE 47, financial year 2025). The company has been active since 2025 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow ReportCompare
LA BRABANÇONNE PHARMAActiveChecked score 54/100
Risk analysis ReportCompare

Overview

Activity
Retail sale of pharmaceutical products
NACE 47730
1 site
Size
€1.2mtotal assets 2025
Staff
3.1 FTE
Equity
€60,175
Loss
-€39,825
Turnover not published (abbreviated format)
Financial health
54 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
1.7%
Structure
Parent
NOVATRIX PHARMA · 100%
2025 accounts 23 days early
Why 54raises riskEquity €60,175 (5.2% of total assets)Founded in 2025Sector: Retail trade (NACE 47)lowers riskSize: 3.1 FTE, total assets €1.2mShow the evidence

Checked score

Score 2025
54 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 40% of its sector peers (NACE 47, micro)
Every signal that counts is listed under Signals.
Financial strength
Average
Solvency 30
equity 5.2% of total assets
Liquidity 55
short-term debt 21.0% · cash 9.1%
Profitability 49
return on assets -3.4%
Bankruptcy probability, 12 months
1.7% Moderate
0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,248 companies, NACE 47, micro)
Last 24 months 08-2026: 1.6%lowest value 09-2026: 1.6%● unchanged vs 08-2026lowest value 10-2026: 1.7%▲ +0.1 percentage points vs 09-2026highest value
Credit of up to €3,000 on 30-day terms is acceptable
Liquidity insufficient (current ratio 0.99, below 1; short-term debt: 21% and cash: 9.1% of total assets), and 94.8% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro): better than 23% on solvency, 60% on liquidity and 36% on profitability.

The bankruptcy probability was computed on 27-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · Equity €60,175 (5.2% of total assets)
NBB · annual accounts
raises risk · Founded in 2025
Companies of this age fail more often than older ones; how much that weighs depends on the rest of its profile.
KBO
lowers risk · Size: 3.1 FTE, total assets €1.2m
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
raises risk · Sector: Retail trade (NACE 47)
KBO
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 17% of 12686 sector peers (2025).
NBB · sector comparison
Position among 12686 sector peers
Solvency
better than 17%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-07-2026, 23 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
23 days early
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
Searched since incorporation in 2025.
KBO publications · our coverage
  1. Annual accounts filedfinancial year 2025 · abbreviated…
  2. IncorporationAppointment: HOUCH Oussama (director) ·…

Key points

  • Caution: Among the weakest 10% on net resultsector median €27,715 · 12,676 companies -€39,825 View
  • Founded 15 months agofounded 18-07-2025 15 months View
  • Controlled by NOVATRIX PHARMA 100% View

By topic

Financials

Financial year
2025
Total assets
€1.2m
Loss
-€39,825
Solvency
5.2%
Go to Financials

Company details

Sites
1
Legal form
Private limited company
Activity
Retail sale of pharmaceutical productsNACE 47730
Founded
18-07-2025
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
30
Who signs
Each director alone
Purpose
“Toutes opérations se rapportant directement ou indirectement aux produits de l’industrie…” (deed in French)
Statutory auditor
No statutory auditor
Go to Articles of association

Key facts about LA BRABANÇONNE PHARMA

What is the company number of LA BRABANÇONNE PHARMA?
1025.693.638. In Belgium the VAT number is the company number with BE in front: BE 1025.693.638.
Where is LA BRABANÇONNE PHARMA based?
The registered office is at Brabançonnelaan 139, 1030 Schaarbeek.Company details
What does LA BRABANÇONNE PHARMA do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of LA BRABANÇONNE PHARMA?
Private limited company (BV).
When was LA BRABANÇONNE PHARMA founded?
On 18-07-2025.
Is LA BRABANÇONNE PHARMA still active?
Yes, LA BRABANÇONNE PHARMA is an active enterprise in the KBO register.
How many employees does LA BRABANÇONNE PHARMA have?
On average 3.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of LA BRABANÇONNE PHARMA?
Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is LA BRABANÇONNE PHARMA profitable?
In financial year 2025, LA BRABANÇONNE PHARMA made a loss of €39,825.
Where can I find the annual accounts of LA BRABANÇONNE PHARMA?
LA BRABANÇONNE PHARMA filed 1 annual account with the National Bank of Belgium, for financial year 2025.

Companies related to LA BRABANÇONNE PHARMA

Go further with this company

How much credit can you give this customer, and on what payment terms?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark Is the workforce growing, and do people stay?Employer check

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure